Despite the fact that many cancer cells are sensitive to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis, some cancer cells show either partial or complete resistance to TRAIL.
Introduction
TNF-related apoptosis-inducing ligand (TRAIL) is a promising cancer therapy that preferentially induces apoptosis in cancer cells [3, 21, 27, 40] . TRAIL is a transmenbrane protein that functions by binding to two closely related receptors, DR4 and DR5. TRAIL is capable of inducing apoptosis in a wide variety of cancer cells but some cancer cell lines show either partial or complete resistance to the pro-apoptotic effects of TRAIL [9, 22, 28, 32, 34] . The reason for the TRAIL resistance is not regulated solely by the differential expression of the receptors. Instead, it appears to be more likely that intracellular inhibitors acting downstream of TRAIL receptors render some cells insensitive to TRAIL since the resistance of many types of cancer cells to TRAIL can be reversed by treatment with chemotherapeutic agents or protein synthesis inhibitors [3, 4, 10, 13, 14, 17, 29, 38] . It has been reported that human leukemic cells showed resistant to TRAIL-induced apoptosis [6, 25, 31] . The study of the intracellular mechanisms that control TRAIL resistance of these leukemic cells might enhance our knowledge of death receptor-mediated signaling and help to develop TRAIL-based approaches for treatment of human leukemia.
There are many factors contributing to the resistance to TRAIL-induced apoptosis. Among the cellular signaling pathways that promote cell survival, Akt, a serine/threonine protein kinase, is one of the important survival factors that contribute resistance to TRAIL [7, 23, 24, 30] . Previous studies have shown that Akt is implicated in mediating a variety of biological responses and plays an important role in survival when cells are exposed to various kinds of apoptotic stimuli [2, 26, 36] . In fact, Akt has been demonstrated to inhibit apoptosis and cytochrome c release induced by several pro-apoptotic Bcl-2 family members [18] . A recent report suggests that phosphorylation of Akt at Ser473 may be mediated by DNA-dependent protein kinase (DNA-PK) [11] .
DNA-PK, a member of the PI3K-related kinase subfamily of protein kinases, is a three-protein complex consisting of Resistance to TRAIL is an important therapeutic problem that may be circumvented by combination treatments that act by various mechanisms including a decrease in c-FLIP levels or restoration of caspase 8 expression [15, 33] . As most agents used in such combinations are inherently toxic, it is imperative to find nontoxic agents. It has been shown that quercetin, a ubiquitous bioactive plant flavonoid, promotes TRAIL-induced apoptotic death by dephosphorylation of Akt in Human prostate adenocarcinoma cells [20] . Quercetin has a wide range of biological activities including induction of apoptosis and inhibition of various enzymes involved in proliferation and in the signal transduction pathway [12] .
Here, we suggest a new resistance mechanism of TRAIL that the DNA-PK pathway plays an essential role in regulating cells to escape from TRAIL-induced apoptosis. We found that quercetin could act in synergy with TRAIL to increase apoptosis by down-regulation of DNA-PK and thus overcome TRAIL-resistance of human leukemic K562 or CEM cells. This study is the first to show that the DNA-PK pathway could interfere with TRAIL-induced apoptotic signaling in human leukemic cells through activation of Akt signaling pathway.
Materials and Methods
Cell culture Cell extract preparation and electrophoretic mobility shift assay (EMSA) Nuclear extracts were prepared from TRAIL and/or quercetin cells as described previously [37] . In brief, 3×10 
Results
Quercetin induced sensitization of TRAIL-resistant K562 cells to TRAIL Primary or cultured leukemia cells are resistant to TRAIL (TNF-related apoptosis-inducing ligand)-induced apoptosis [16] . The molecular factors regulating the sensitivity to TRAIL are still incompletely understood in the TRAIL-resistant cells. Therefore, to investigate the potential mechanism of leukemic cells resistant to TRAIL, we determined the susceptibility to TRAIL-induced apoptosis of K562 cells.
When K562 cells were treated with TRAIL (10-and 50 ng/ml) for 24 hr, TRAIL-induced apoptosis in K562 cells was not observed with TRAIL alone (Fig. 1A) . These results suggest that down-regulation of DNA-PK might be associated with an increase in susceptibility to TRAIL-induced apoptosis via reduction of Akt phosphorylation.
We next determined whether inhibition of DNA-PK/Akt pathway and subsequently activation of apoptosis machinery occurred in K562 cells by combined treatment of quercetin (20 μM) and TRAIL (10-or 50 ng/ml) (Fig. 3A) . As
(C) 
Sensitization of CEM cells to TRAIL by quercetin
Since we found that quercetin enhanced TRAIL response of K562 cells by inhibition of DNA-PK signaling pathway, we also examined whether quercetin promotes TRAIL-induced apoptosis in other human leukemic cells (Fig. 5) .
When human leukemic lymphoid CEM cells were treated A variety of reports has suggested the role of Akt in chemotherapeutic resistance to apoptosis and indicated its prosurvival function [7, 23, 24, 26, 30] . Indeed, it has been reported that activated Akt subsequently phosphorylates and inactivates several proapoptotic molecules including TRAIL and thus down-regulation of Akt activity promotes TRAIL cytotoxicity [2, 36] .
In addition to having a role in DSB repair of DNA-PK, the DNA-PK catalytic subunit, a member of PI3K family, performs an essential phosphorylation on Akt Ser-473 [8] .
Since DNA-PKcs physiologically interacts with and activates Akt, it is very possible that both DNA-PK and Akt activities contribute to cancerous cell survival.
In this study, we suggest that the susceptibility to TRAIL-induced cytotoxicity is associated with inhibition of DNA-PK/Akt signaling cascade in human leukemic cells. DNA-PK acts upstream to Akt and is important for both phosphorylation and activation of Akt. Indeed, it has been reported that tumor cells resistant to anticancer drugs show increases in both DNA-PK expression and its kinase activity [35] , and the use of inhibitor that possesses inhibitory action of DNA-PK activity improved the effectiveness of anticancer drug [19, 41] , suggesting that DNA-PK may play an important role in the development of drug resistance.
Therefore, TRAIL in combination with agents that down-regulate DNA-PK can have clinical applicability in treating TRAIL-insensitive human leukemic cells.
Quercetin is known to inhibit Akt phosphorylation as well as expert multiple effects on cellular growth and apoptosis [34] . We found that quercetin possesses inhibitory action of expression and activity of both DNA-PK and Akt at high concentration, suggesting possibility that quercetin could potentiate TRAIL-induced apoptosis by inhibition of DNA-PK and p-Akt signaling cascade.
Our data showed that quercetin potentiated TRAIL-medi- 
